Skip to main content

Alzheimer's Disease

Symposium celebrates open science, launches new data platform

Suzana PETANCESKA, Program Officer, Division of Neuroscience (DN)
It was great to see so many of you at the Alzheimer’s Association International Conference last month! I was thrilled to catch up with colleagues, attend the special events, and learn about many new Alzheimer’s research findings. In case you missed it, NIA and the Alzheimer’s Association hosted a pre-conference symposium: “Enabling Precision Medicine for Alzheimer’s Disease Through Open Science.”

Together we make the difference in Alzheimer's and related dementias research: NIH's FY 2020 bypass budget and progress report

Richard HODES, Director, Office of the Director (OD)
On Monday, July 30, I presented, on behalf of NIH Director Dr. Francis Collins, the Fiscal Year 2020 NIH Professional Judgment Budget for Alzheimer’s Disease and Related Dementias at the meeting of the HHS Secretary’s Advisory Council on Alzheimer’s Research, Care, and Services. The estimate—commonly referred to as a Bypass Budget—is based on scientific opportunities that NIH could pursue to achieve the research goal of the National Plan to Address Alzheimer’s Disease—to prevent and effectively treat Alzheimer’s disease by 2025. 

Yes! We mean NIA grantees too...

Robin BARR, Director, DEA, Division of Extramural Activities (DEA)
If we roll back the clock 12 months, we’ll see that, back then, NIA issued a call for administrative supplements for existing NIA grantees to add an aim on Alzheimer’s disease (and its related dementias) to a grant that was not already studying Alzheimer’s or its related dementias. This year, we decided to open the field up a little and include other NIH institutes.

Now is the time! NIA's small business programs offer up to $1.5 million in no-strings-attached funding

Michael-David KERNS, Health Scientist Administrator, Division of Extramural Activities (DEA)
If you run a small business, are thinking of starting a small business, or have an idea focused on Alzheimer's disease and Alzheimer’s-related dementias (AD/ADRD) that has a commercial side, then this blog is for you! Whether your focus is therapeutic drug development, systems of care, effects on families, or something else, there are opportunities for you through our small business research and development programs – known as SBIR (Small Business Innovation Research) and STTR (Small Business Technology Transfer Research).

BSR seeks wins in a new arena: AD/ADRD

Dana PLUDE, Deputy Director, DBSR, Division of Behavioral and Social Research (DBSR)
March Madness—a time for bracket busting and bragging rights, Cinderella stories and unexpected outcomes. And, so it goes in NIA-supported research, too! We in the Division of Behavioral and Social Research have been developing our game in new directions—funding more research in Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD).

New opportunities announced for next-gen Alzheimer’s Disease Research Centers grants

Richard HODESNina SILVERBERG, Director, Office of the Director (OD)
The NIA-supported Alzheimer’s Disease Centers (ADCs) have long been a crucial part of NIA’s overall Alzheimer’s disease program and have many accomplishments to their credit. During this time of expanding interest and support for Alzheimer’s research, NIA is introducing important changes to this Centers program.

A long story about a strange way to publish funding opportunities: Or, just another day at the office

Robin BARR, Director, DEA, Division of Extramural Activities (DEA)
Here we go again. Maybe. The U.S. House and Senate appropriations committees have written large increases into their appropriations bills for NIA—again in FY 2018—to expand research into Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD).

A new era of clinical trials in Alzheimer’s disease and related dementias

Laurie RYAN, Chief, Dementias of Aging Branch, Division of Neuroscience (DN)
You may have already heard that the NIA has awarded a new cooperative agreement establishing the Alzheimer’s Clinical Trial Consortium (ACTC). We expect the ACTC to accelerate and expand studies for therapies in Alzheimer’s disease and related dementias. We hope you’ve also heard that the funding opportunity for ACTC trials is open. The first submission date for applications is March 29 and we strongly encourage interested investigators to reach out to the ACTC leadership and NIA well in advance.